HUTCHMED to Host Expert Call on Immune Thrombocytopenia
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) has announced that it will hold a physician expert call featuring a professor and key opinion leader in the field of immune thrombocytopenia (ITP). This discussion will focus on the current treatment landscape for ITP and will be available via webcast on an upcoming date at 7:00 p.m. HKT.
Event Details
The event will be conducted in Chinese (Putonghua) and can be accessed at www.hutch-med.com/event. Investors who wish to participate in the webcast should log on before the start time to ensure they have any necessary software downloaded. A transcript of the event, including an English translation, will be made available shortly after, for approximately 90 days. Please note that this event is designed exclusively for investor audiences.
About ESLIM-01 Trial
ESLIM-01 is a Phase III trial investigating HUTCHMED’s innovative investigational drug candidate, sovleplenib, in patients diagnosed with primary ITP. The trial successfully met all its endpoints, and the results were published in a well-regarded medical journal as well as presented at the European Hematology Association Hybrid Congress. Recently, HUTCHMED submitted a New Drug Application for sovleplenib.
Understanding Immune Thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is an autoimmune disorder that leads to the destruction of platelets and a reduction in their production. Patients suffering from ITP face an increased risk of excessive bleeding and bruising, along with symptoms such as fatigue and a diminished quality of life. The incidence of primary ITP in adults is approximately 3.3 cases per 100,000 adults each year, with an estimated prevalence of 9.5 per 100,000 adults. Based on this data, it is estimated that around 110,000 individuals are living with primary ITP in major markets.
Sovleplenib’s Role in Treatment
Sovleplenib is a novel, selective Syk inhibitor designed for once-daily oral administration. Syk plays a crucial role in B-cell receptor and FcR signaling, making it a promising target for various B-cell lymphomas and autoimmune disorders. HUTCHMED is currently conducting clinical investigations into sovleplenib, retaining all global rights to the drug.
Other Indications for Sovleplenib
Beyond its use in ITP, sovleplenib is also being explored for its potential in treating warm antibody autoimmune hemolytic anemia and indolent non-Hodgkin’s lymphoma.
About HUTCHMED
HUTCHMED is a forward-thinking, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for cancer and immunological diseases. The company boasts a workforce of approximately 5,000 employees, with a significant number dedicated to oncology and immunology. HUTCHMED is committed to delivering its cancer drug candidates to patients globally, having made notable progress with its first three medicines now available in select regions.
Frequently Asked Questions
What is the purpose of the HUTCHMED expert call?
The expert call is designed to discuss the treatment landscape of immune thrombocytopenia and to provide insights regarding the company’s drug candidates.
What is sovleplenib?
Sovleplenib is a novel drug candidate currently under investigation for the treatment of ITP and other autoimmune disorders, specifically targeting Syk.
Who can attend the webcast?
The webcast is intended for investor audiences, and interested individuals should log in before the scheduled start time.
What is the incidence of ITP?
The incidence of primary ITP is approximately 3.3 cases per 100,000 adults each year.
How can I learn more about HUTCHMED?
To find out more about HUTCHMED, you can visit their official website or explore their communication channels for additional information.
